Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB 258719 is a selective antagonist of 5-HT7 receptor(pKi of 7.5).
ターゲット&IC50 | 5-HT7 receptor:7.5 (pKi) |
In vitro | SB 258719 antagonised surmountably 5-CT-stimulated adenylyl cyclase activity. Schild analysis of the antagonism by SB 258719 gave a pA2 of 7.2±0.2 and slope not significantly different from 1, consistent with competitive antagonism[3]. |
In vivo | SB 258719 (5-20 mg/kg, i.p.) reversed the hypothermic effect of 5-CT in mice[1]. Increased Wnt/β-catenin activity was attenuated by SB 258719 in HCC cell lines and patient-derived primary tumour tissues in the presence of 5-HT. SB 258719 also reduced tumour growth in vivo[2]. |
分子量 | 338.51 |
分子式 | C18H30N2O2S |
CAS No. | 195199-95-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (738.53 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SB 258719 195199-95-2 GPCR/G Protein Neuroscience 5-HT Receptor 5-hydroxytryptamine Receptor agonism Inhibitor inverse SB258719 hydrochloride partial apparent selective inhibit SB-258719 Serotonin Receptor affinity inhibitor